Pre-IPO Hangzhou Jiuyuan Gene Engineering - Old Pipelines Are Difficult to Bring New Breakthroughs
Jiuyuan's pipelines lack high moat since most are generic pharmaceuticals and relatively old products. If its GLP-1s fail to show superior clinical...
No more insights